W. Novotny

Cancer Research · 2003–2023

A researcher in the Science corpus: 9 papers; trusts 2 researchers and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

Whom W. Novotny trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. N. Ferrara

Who trusts W. Novotny overall

  1. N. Ferrara
  2. J. Joyce
  3. M. Shibuya

Papers from W. Novotny's perspective

Ordered by how strongly the researchers W. Novotny trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Clinical translation of angiogenesis inhibitors (Nature Reviews. Cancer)
  2. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. (Journal of Clinical Oncology)
  3. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 (Nature Medicine)
  4. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (Nature Cell Biology)
  5. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. (Journal of Clinical Investigation)
  6. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. (Journal of Clinical Investigation)
  7. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. (Journal of Clinical Oncology)
  8. VEGF-Trap: A VEGF blocker with potent antitumor effects (Proceedings of the National Academy of Sciences of the United States of America)
  9. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug (Nature reviews. Drug discovery)
  10. The biology of VEGF and its receptors (Nature Medicine)

Their papers